预处理血管生成细胞因子可预测慢性淋巴细胞白血病患者对化疗免疫治疗的反应。
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.
机构信息
Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
出版信息
Br J Haematol. 2009 Sep;146(6):660-4. doi: 10.1111/j.1365-2141.2009.07811.x. Epub 2009 Jul 10.
Abstract
Serum levels of pro-[vascular endothelial growth factor (VEGF)] and anti-[thrombospondin-1 (TSP)] angiogenic cytokines were prospectively measured in a phase II trial of chemoimmunotherapy (CIT) for chronic lymphocytic leukaemia (CLL) patients (n = 56). Pretreatment VEGF levels were lower among patients who achieved complete remission (CR) or nodular partial remission (nPR) relative to those with partial remission (PR) or stable/progressive disease (median 122.0 pg/ml vs. 246.8 pg/ml; P = 0.03). VEGF:TSP ratio was lower (anti-angiogenic phenotype) among patients who achieved CR/nPR. The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT.
摘要
在一项针对慢性淋巴细胞白血病（CLL）患者的化疗免疫治疗（CIT）的 II 期试验中，前瞻性地测量了血清中促血管内皮生长因子（VEGF）和抗血栓素-1（TSP）血管生成细胞因子的水平（n=56）。与部分缓解（PR）或稳定/进展性疾病患者相比，达到完全缓解（CR）或结节部分缓解（nPR）的患者的 VEGF 水平较低（中位数 122.0 pg/ml 与 246.8 pg/ml；P=0.03）。达到 CR/nPR 的患者的 VEGF:TSP 比值较低（抗血管生成表型）。VEGF:TSP 比值也与总生存期相关（P=0.008）。在接受 CIT 的 CLL 患者中，促血管生成谱似乎与反应减弱和生存不良相关。
相似文献
1
Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia.预处理血管生成细胞因子可预测慢性淋巴细胞白血病患者对化疗免疫治疗的反应。
Br J Haematol. 2009 Sep;146(6):660-4. doi: 10.1111/j.1365-2141.2009.07811.x. Epub 2009 Jul 10.
2
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).奥法妥木单抗联合化疗在未经治疗的慢性淋巴细胞白血病（CLL）患者中具有疗效且耐受性良好。
Cancer. 2013 Nov 1;119(21):3788-96. doi: 10.1002/cncr.28292. Epub 2013 Aug 6.
3
Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.基于社区的喷司他丁、环磷酰胺和利妥昔单抗（PCR）生物化疗用于慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的II期试验。
Cancer Biother Radiopharm. 2007 Apr;22(2):185-93. doi: 10.1089/cbr.2007.332.
4
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
5
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).泊马度胺、环磷酰胺和利妥昔单抗后继以阿仑单抗治疗复发或难治性慢性淋巴细胞白血病：ECOG-ACRIN 癌症研究组（E2903）的 2 期试验。
Acta Haematol. 2019;142(4):224-232. doi: 10.1159/000500164. Epub 2019 Jul 23.
6
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.氟达拉滨、环磷酰胺、阿仑单抗和利妥昔单抗联合一线治疗高危慢性淋巴细胞白血病。
Blood. 2011 Aug 25;118(8):2062-8. doi: 10.1182/blood-2011-01-329177. Epub 2011 Jul 12.
7
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.一项随机II期试验，比较化疗免疫疗法联合或不联合贝伐单抗用于既往未接受治疗的慢性淋巴细胞白血病患者的疗效。
Oncotarget. 2016 Nov 29;7(48):78269-78280. doi: 10.18632/oncotarget.13412.
8
Community-based phase II trial of PCR for CLL/SLL patients.针对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的基于社区的PCR II期试验。
Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7. doi: 10.1089/cbr.2007.0424.
9
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].[碱性成纤维细胞生长因子（bFGF）和血管内皮生长因子（VEGF）在慢性淋巴细胞白血病患者的外周血血浆中升高，且在基于氟达拉滨的强化治疗后降低]
Vnitr Lek. 2007 Nov;53(11):1171-6.
10
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.喷司他丁、环磷酰胺和利妥昔单抗联合化疗免疫疗法在既往未治疗的B细胞慢性淋巴细胞白血病中显示出显著的临床活性且伴随毒性较低。
Blood. 2007 Jan 15;109(2):405-11. doi: 10.1182/blood-2006-07-033274. Epub 2006 Sep 28.
引用本文的文献
1
Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?慢性淋巴细胞白血病中的肿瘤细胞存活因子与血管生成：二者关联有多紧密？
Cancers (Basel). 2024 Dec 29;17(1):72. doi: 10.3390/cancers17010072.
2
Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms.伴t(1;19)染色体易位的骨髓增生异常综合征继发胃癌：1例罕见病例报告及其潜在机制
Medicine (Baltimore). 2018 Jul;97(30):e11535. doi: 10.1097/MD.0000000000011535.
3
Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue.乳腺肿瘤组织中血小板反应蛋白-1和血管内皮生长因子的预测模型
NPJ Syst Biol Appl. 2016;2:16030-. doi: 10.1038/npjsba.2016.30. Epub 2016 Oct 20.
4
A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.一项随机II期试验，比较化疗免疫疗法联合或不联合贝伐单抗用于既往未接受治疗的慢性淋巴细胞白血病患者的疗效。
Oncotarget. 2016 Nov 29;7(48):78269-78280. doi: 10.18632/oncotarget.13412.
5
Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.血管内皮生长因子A（VEGFA）基因多态性对慢性淋巴细胞白血病惰性患者亚组的生存有影响。
PLoS One. 2014 Jun 27;9(6):e101063. doi: 10.1371/journal.pone.0101063. eCollection 2014.
6
Critical signal transduction pathways in CLL.慢性淋巴细胞白血病的关键信号转导通路。
Adv Exp Med Biol. 2013;792:215-39. doi: 10.1007/978-1-4614-8051-8_10.
7
Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia.抗 VEGF 单药治疗慢性淋巴细胞白血病患者的 II 期临床试验。
Leuk Lymphoma. 2010 Dec;51(12):2222-9. doi: 10.3109/10428194.2010.524327. Epub 2010 Nov 5.
本文引用的文献
1
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗方案作为慢性淋巴细胞白血病初始治疗的长期结果
Blood. 2008 Aug 15;112(4):975-80. doi: 10.1182/blood-2008-02-140582. Epub 2008 Apr 14.
2
[Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].[碱性成纤维细胞生长因子（bFGF）和血管内皮生长因子（VEGF）在慢性淋巴细胞白血病患者的外周血血浆中升高，且在基于氟达拉滨的强化治疗后降低]
Vnitr Lek. 2007 Nov;53(11):1171-6.
3
4
Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".骨活检获得的骨髓基质成分可挽救慢性淋巴细胞白血病B细胞免于自发和药物诱导的细胞死亡，并促进“血管生成开关”。
Leuk Res. 2007 Jul;31(7):899-906. doi: 10.1016/j.leukres.2006.11.024. Epub 2007 Jan 22.
5
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.单独使用紫杉醇-卡铂或联合贝伐单抗治疗非小细胞肺癌。
N Engl J Med. 2006 Dec 14;355(24):2542-50. doi: 10.1056/NEJMoa061884.
6
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.喷司他丁、环磷酰胺和利妥昔单抗联合化疗免疫疗法在既往未治疗的B细胞慢性淋巴细胞白血病中显示出显著的临床活性且伴随毒性较低。
Blood. 2007 Jan 15;109(2):405-11. doi: 10.1182/blood-2006-07-033274. Epub 2006 Sep 28.
7
The history of the angiogenic switch concept.血管生成开关概念的历史。
Leukemia. 2007 Jan;21(1):44-52. doi: 10.1038/sj.leu.2404402. Epub 2006 Sep 21.
8
The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia.慢性淋巴细胞白血病中新生血管形成和血管生成信号通路的临床及生物学重要性
Semin Oncol. 2006 Apr;33(2):174-85. doi: 10.1053/j.seminoncol.2006.01.008.
9
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.氟达拉滨联合环磷酰胺与单用氟达拉滨用于年轻慢性淋巴细胞白血病患者的一线治疗比较
Blood. 2006 Feb 1;107(3):885-91. doi: 10.1182/blood-2005-06-2395. Epub 2005 Oct 11.
10
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.氟达拉滨、环磷酰胺和利妥昔单抗化疗免疫疗法作为慢性淋巴细胞白血病初始治疗的早期结果。
J Clin Oncol. 2005 Jun 20;23(18):4079-88. doi: 10.1200/JCO.2005.12.051. Epub 2005 Mar 14.
Zotero 插件